Literature DB >> 21092706

Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.

Delaram Doroud1, Alireza Vatanara, Farnaz Zahedifard, Elham Gholami, Rouhollah Vahabpour, Abdolhossein Rouholamini Najafabadi, Sima Rafati.   

Abstract

PURPOSE: Leishmaniasis is a major health problem in many tropical and sub-tropical countries and development of a safe and easily-available vaccine has high priority. Although several antigens potentially capable of inducing protective immunity have been studied, in the absence of pharmaceutical industry interest they have remained as fine publications only. Amongst them, Cathepsin L-like cysteine proteinases (CPs) have received considerable attention and type I and II CPs have been used in a heterologous prime-boost vaccination regime for experimental visceral leishmaniasis in dogs. Due to the promising results of the mentioned vaccination regime, we aimed to evaluate cationic solid lipid nanoparticles (cSLNs) for in vitro delivery of cpa, cpb and cpb(CTE) intended to be used as a cocktail DNA vaccine in our forthcoming studies.
METHODS: cSLNs were formulated of cetyl palmitate, cholesterol, DOTAP and Tween 80 via melt emulsification method followed by high shear homogenization. Different formulations were prepared by anchoring pDNAs on the surface of cSLNs via charge interaction. The formulations were characterized according to their size and zeta potential as well as pDNA integrity and stability against DNase I treatment. Lipoplexes' cytotoxicity was investigated on COS-7 cells by MTT test. The effect of the DOTAP:pDNA ratio on protection ability and cytotoxicity was also studied. In vitro transfection efficiency was qualified by fluorescent microscopy and quantified using flow cytometry technique.
RESULTS: cSLN-pDNA complexes were formulated with suitable size and zeta potential. Efficiency/cytotoxicity ratio of cSLN-pDNAs formulations was comparable to linear PEI-25KD-pDNAs polyplexes while exhibiting significantly lower cytotoxicity.
CONCLUSION: Tested formulations were able to deliver immunogenic CP genes efficiently. This data proves the ability of this system as a promising DNA vaccine carrier for leishmaniasis to cover the main drawback of naked pDNA delivery that is rapid elimination from the circulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21092706     DOI: 10.18433/j3r30t

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

1.  Effects of base polymer hydrophobicity and end-group modification on polymeric gene delivery.

Authors:  Joel C Sunshine; Marib I Akanda; David Li; Kristen L Kozielski; Jordan J Green
Journal:  Biomacromolecules       Date:  2011-09-09       Impact factor: 6.988

2.  C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.

Authors:  Delaram Doroud; Farnaz Zahedifard; Alireza Vatanara; Yasaman Taslimi; Rouholah Vahabpour; Fatemeh Torkashvand; Behrooz Vaziri; Abdolhossein Rouholamini Najafabadi; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2011-07-12

3.  Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A.

Authors:  Ling Zhang; Xiang Gao; Ke Men; Bilan Wang; Shuang Zhang; Jinfeng Qiu; Meijuan Huang; Maling Gou; Ning Huang; Zhiyong Qian; Xia Zhao; Yuquan Wei
Journal:  Int J Nanomedicine       Date:  2011-10-19

4.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27

Review 5.  Leishmaniasis in humans: drug or vaccine therapy?

Authors:  Masoud Ghorbani; Ramin Farhoudi
Journal:  Drug Des Devel Ther       Date:  2017-12-22       Impact factor: 4.162

6.  DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica.

Authors:  Elham Gholami; Fabiano Oliveira; Tahereh Taheri; Negar Seyed; Safoora Gharibzadeh; Nasim Gholami; Amir Mizbani; Fatemeh Zali; Sima Habibzadeh; Daniel Omid Bakhadj; Claudio Meneses; Kambiz Kamyab-Hesari; Alireza Sadeghipour; Yasaman Taslimi; Fatemeh Khadir; Shaden Kamhawi; Mohammad Ali Mazlomi; Jesus G Valenzuela; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2019-01-11

7.  Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahereh Taheri; Farnaz Zahedifard; Yasaman Taslimi; Fatemeh Doustdari; Azam Bolhassani; Delaram Doroud; Hiva Azizi; Kazem Heidari; Mohammad Vasei; Nabiollah Namvar Asl; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.